A clarithromycin-rezisztencia magyarországi epidemiológiája Helicobacter pylori-fertozésben

Translated title of the contribution: The Hungarian epidemiology of clarithromycin resistance in Helicobacter pylori infection

György Miklós Buzás, G. Lotz, András Kiss

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Introduction: Antibiotic susceptibility is a major determinant of the eradication treatment outcome and its local determination is recommended in all regions. Aims: The purpose of the study is the assessment of the current prevalence of clarithromycin resistance in our district and an overview of the Hungarian data. Metbods: A) Biopsy samples were randomly selected from 238 cases examined at the Department of Gastroenterology. The resistance to chlarithromycin was determined by fluorescence in situ hibridization. B) Hungarian congress abstracts dealing with resistance to clarithromycin, published between 1995 and 2006, were reviewed and the prevalence and change over time of the resistance was studied. The use of clarithromycin since its introduction in 1993 was analysed. Results: A) The prevalence of primary clarithromycin resistance was 17.3%. and it was complete in 47.4% and partial in 52.6%. The rate of secondary resistance was of 55.5%. There was a weak positive correlation between age (r = 0.15), female gender (r = 0,10) and smoking (r = 0,16) and prevalence of resistance. B) Claritromycin resistance was addressed in 8 papers, including 775 cases. The prevalence of resistance determined by phenotypic methods was 3,9%, while fluorescence in situ hibridization detected the resistance in 17.0% of the cases. Regional differences were encountered. Secondary resistance was met in 55.5% using phenotypic and in 49.0% with genotypic methods. C) The use of clarithromycin increased fivefold between 1993-2005. Discussion: The prevalence of clarithromycin resistance determined by genotypic method is increased as compared to the results of earlier phenotypic methods, which could be due to the more extensive use of macrolides.

Original languageHungarian
Pages (from-to)1461-1467
Number of pages7
JournalOrvosi Hetilap
Volume148
Issue number31
DOIs
Publication statusPublished - Aug 5 2007

Fingerprint

Clarithromycin
Helicobacter Infections
Helicobacter pylori
Epidemiology
Fluorescence
Macrolides
Gastroenterology
Smoking
Anti-Bacterial Agents
Biopsy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A clarithromycin-rezisztencia magyarországi epidemiológiája Helicobacter pylori-fertozésben. / Buzás, György Miklós; Lotz, G.; Kiss, András.

In: Orvosi Hetilap, Vol. 148, No. 31, 05.08.2007, p. 1461-1467.

Research output: Contribution to journalArticle

Buzás, György Miklós ; Lotz, G. ; Kiss, András. / A clarithromycin-rezisztencia magyarországi epidemiológiája Helicobacter pylori-fertozésben. In: Orvosi Hetilap. 2007 ; Vol. 148, No. 31. pp. 1461-1467.
@article{78e9b435841c4d7ab7e1332228a6fd18,
title = "A clarithromycin-rezisztencia magyarorsz{\'a}gi epidemiol{\'o}gi{\'a}ja Helicobacter pylori-fertoz{\'e}sben",
abstract = "Introduction: Antibiotic susceptibility is a major determinant of the eradication treatment outcome and its local determination is recommended in all regions. Aims: The purpose of the study is the assessment of the current prevalence of clarithromycin resistance in our district and an overview of the Hungarian data. Metbods: A) Biopsy samples were randomly selected from 238 cases examined at the Department of Gastroenterology. The resistance to chlarithromycin was determined by fluorescence in situ hibridization. B) Hungarian congress abstracts dealing with resistance to clarithromycin, published between 1995 and 2006, were reviewed and the prevalence and change over time of the resistance was studied. The use of clarithromycin since its introduction in 1993 was analysed. Results: A) The prevalence of primary clarithromycin resistance was 17.3{\%}. and it was complete in 47.4{\%} and partial in 52.6{\%}. The rate of secondary resistance was of 55.5{\%}. There was a weak positive correlation between age (r = 0.15), female gender (r = 0,10) and smoking (r = 0,16) and prevalence of resistance. B) Claritromycin resistance was addressed in 8 papers, including 775 cases. The prevalence of resistance determined by phenotypic methods was 3,9{\%}, while fluorescence in situ hibridization detected the resistance in 17.0{\%} of the cases. Regional differences were encountered. Secondary resistance was met in 55.5{\%} using phenotypic and in 49.0{\%} with genotypic methods. C) The use of clarithromycin increased fivefold between 1993-2005. Discussion: The prevalence of clarithromycin resistance determined by genotypic method is increased as compared to the results of earlier phenotypic methods, which could be due to the more extensive use of macrolides.",
keywords = "Antimicrobial resistance, Clarithromycin, Fluorescent in situ hibridization, Helicobacter pylori",
author = "Buz{\'a}s, {Gy{\"o}rgy Mikl{\'o}s} and G. Lotz and Andr{\'a}s Kiss",
year = "2007",
month = "8",
day = "5",
doi = "10.1556/OH.2007.28013",
language = "Hungarian",
volume = "148",
pages = "1461--1467",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "31",

}

TY - JOUR

T1 - A clarithromycin-rezisztencia magyarországi epidemiológiája Helicobacter pylori-fertozésben

AU - Buzás, György Miklós

AU - Lotz, G.

AU - Kiss, András

PY - 2007/8/5

Y1 - 2007/8/5

N2 - Introduction: Antibiotic susceptibility is a major determinant of the eradication treatment outcome and its local determination is recommended in all regions. Aims: The purpose of the study is the assessment of the current prevalence of clarithromycin resistance in our district and an overview of the Hungarian data. Metbods: A) Biopsy samples were randomly selected from 238 cases examined at the Department of Gastroenterology. The resistance to chlarithromycin was determined by fluorescence in situ hibridization. B) Hungarian congress abstracts dealing with resistance to clarithromycin, published between 1995 and 2006, were reviewed and the prevalence and change over time of the resistance was studied. The use of clarithromycin since its introduction in 1993 was analysed. Results: A) The prevalence of primary clarithromycin resistance was 17.3%. and it was complete in 47.4% and partial in 52.6%. The rate of secondary resistance was of 55.5%. There was a weak positive correlation between age (r = 0.15), female gender (r = 0,10) and smoking (r = 0,16) and prevalence of resistance. B) Claritromycin resistance was addressed in 8 papers, including 775 cases. The prevalence of resistance determined by phenotypic methods was 3,9%, while fluorescence in situ hibridization detected the resistance in 17.0% of the cases. Regional differences were encountered. Secondary resistance was met in 55.5% using phenotypic and in 49.0% with genotypic methods. C) The use of clarithromycin increased fivefold between 1993-2005. Discussion: The prevalence of clarithromycin resistance determined by genotypic method is increased as compared to the results of earlier phenotypic methods, which could be due to the more extensive use of macrolides.

AB - Introduction: Antibiotic susceptibility is a major determinant of the eradication treatment outcome and its local determination is recommended in all regions. Aims: The purpose of the study is the assessment of the current prevalence of clarithromycin resistance in our district and an overview of the Hungarian data. Metbods: A) Biopsy samples were randomly selected from 238 cases examined at the Department of Gastroenterology. The resistance to chlarithromycin was determined by fluorescence in situ hibridization. B) Hungarian congress abstracts dealing with resistance to clarithromycin, published between 1995 and 2006, were reviewed and the prevalence and change over time of the resistance was studied. The use of clarithromycin since its introduction in 1993 was analysed. Results: A) The prevalence of primary clarithromycin resistance was 17.3%. and it was complete in 47.4% and partial in 52.6%. The rate of secondary resistance was of 55.5%. There was a weak positive correlation between age (r = 0.15), female gender (r = 0,10) and smoking (r = 0,16) and prevalence of resistance. B) Claritromycin resistance was addressed in 8 papers, including 775 cases. The prevalence of resistance determined by phenotypic methods was 3,9%, while fluorescence in situ hibridization detected the resistance in 17.0% of the cases. Regional differences were encountered. Secondary resistance was met in 55.5% using phenotypic and in 49.0% with genotypic methods. C) The use of clarithromycin increased fivefold between 1993-2005. Discussion: The prevalence of clarithromycin resistance determined by genotypic method is increased as compared to the results of earlier phenotypic methods, which could be due to the more extensive use of macrolides.

KW - Antimicrobial resistance

KW - Clarithromycin

KW - Fluorescent in situ hibridization

KW - Helicobacter pylori

UR - http://www.scopus.com/inward/record.url?scp=34848860516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848860516&partnerID=8YFLogxK

U2 - 10.1556/OH.2007.28013

DO - 10.1556/OH.2007.28013

M3 - Article

VL - 148

SP - 1461

EP - 1467

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 31

ER -